Curium in Advanced Talks to Acquire Lantheus for About $7 Billion
Curium is in advanced talks to buy Lantheus for ~$7B ($102/share + $12.50 CVRs). Announcement possible soon; no final deal confirmed yet.
Curium is in advanced talks to buy Lantheus for ~$7B ($102/share + $12.50 CVRs). Announcement possible soon; no final deal confirmed yet.
Piper sees Intuitive Surgical staying ahead in robotic surgery, with strong growth potential despite rising competition.
Ronald Fischer, convicted of sexual assault, evaded justice for over two decades while living under the alias Richard Graydon as CMO of Immix Biopharma.
Abivax has resumed partnership talks with major pharma companies via Centerview Partners while preparing a potential independent U.S. launch of obefazimod.
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
Novo Nordisk’s Wegovy pill is dominating early sales with 8x more prescriptions than Eli Lilly’s Foundayo.